SpinDiag
Develops an easy-to-use, compact, and automated point-of-care system for the broad, fast, and affordable screening of infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | €15.0m | Debt | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Spindiag GmbH is a healthcare technology company specializing in rapid point-of-care diagnostic solutions for infectious diseases. The company operates primarily in the healthcare sector, serving hospitals, clinics, and other medical facilities that require immediate and accurate testing for infectious diseases such as COVID-19. Spindiag's core product, the Rhonda PCR rapid test, provides results for up to 60 patients per device daily, enabling healthcare providers to make quick decisions about patient quarantine and treatment. The business model focuses on selling diagnostic devices and test kits to medical institutions, generating revenue through the sale of these products and associated consumables. Spindiag's market includes both public and private healthcare providers who need efficient and reliable testing solutions to manage infectious disease outbreaks. The company aims to increase patient safety while reducing healthcare costs through its innovative technology.
Keywords: point-of-care, infectious diseases, rapid testing, healthcare technology, Rhonda PCR, diagnostic solutions, patient safety, quarantine decisions, medical devices, cost-efficient.